Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis

OSAKA Japan and CAMBRIDGE, Massachusetts, November 7, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials